Our Clinical Flow Cytometry Services start with expert assay development and optimization and end with reliable data conducted in state-of-the-art service laboratories under relevant regulatory compliance (CLIA-certified, CAP-accredited, and GCLP compliant)
Discovery's Clinical Flow Cytometry Service Advantages
State of the Art Technologies
High-resolution spectral flow cytometry data at the single-cell level using Cytek® Aurora systems
Up to 40-markers simultaneously for comprehensive answers to critical questions
Expert Assay Development and Validation
Expert consultation to design custom panels and rigorously validate assays
Technology transfer of client developed custom panels
Customized Solutions for Clients
Approach every project like a partnership to foster trust and client retention
Dedicated expert scientific support and direct communications throughout every clinical trial project
Flexibility
We can start projects quickly and offer short timelines
Integrated capabilities to accelerate new assay development or technology transfer
Biospecimens and Multi-omics Services Under One Roof
Access to the largest, most characterized commercial biorepository for validation samples
Adjacent to genomics, proteomics, and molecular pathology service laboratories
Single chain of custody and optimized logistics
Clinical Flow Cytometry Services
Our experts have designed an industry-leading approach that starts with careful assay development and optimization to meet CAP, CLIA and GCLP guidelines.
Detect biomarkers across a broad range of normal and diseased samples
Comprehensive immunoprofiling of patient samples: up to 40 markers/colors simultaneously.
Develop custom assays to meet customer needs as well as ability to perform technology transfer of client-developed panels from similar or different platforms.
Assess target engagement, drug efficacy, receptor occupancy, and mechanism of action.
Testing of exploratory/retrospective (RUO) and prospective (CAP/CLIA) clinical trial patient samples
Understand targets in preclinical models and accelerate transition to the next stage of development
Advanced biomarker detection by flow cytometry with up to 40 markers measured simultaneously for custom assay development and tech transfer, and assessment of target engagement, drug efficacy, and mechanism of action in exploratory and clinical trial samples.